Emerging Companies in the South Korea Leprosy Market | Insights 2026

Emerging Companies in the South Korea Leprosy Market

The SouthKorea leprosy market is highly specialized, with a transition from historical endemic management to a framework focused on monitoring sporadic, imported cases and providing advanced rehabilitative care. The market depends on a synergy between global pharmaceutical innovators, public health surveillance by the Korean government, and leading domestic biotechnology players. The key players in the market are the Ministry of Health and Welfare, WHO, Novartis, Handok, Daewon Pharmaceutical, JW Pharmaceutical, Boryung, SK Chemicals, Celltrion and Samsung Biologics.

South Korea Leprosy Market Overview

According to 6Wresearch, the South Korea leprosy market is a precise healthcare infrastructure, within the existing healthcare system, dedicated to sporadic and rare case management, and the long-term management of leprosy-related disability. The present model is patient-oriented, with specialized infectious disease management and state of the art rehabilitative care.

This generates a need for effective and affordable drugs, as there is a need for strict adherence to Multi-Drug Therapy protocols, as recommended by WHO, to ensure clearance of bacteria and avoid long-term complications. The treatments are highly effective clinically and strictly regulated, and are available through specialized tertiary hospitals and authorized public health channels.

Competitive Landscape

The competitive landscape of the South Korea leprosy industry includes multinational giants that provide global therapeutic donations and innovation, while major domestic pharmaceutical companies ensure the availability of essential anti-infectives locally, and support the wider national pharmaceutical ecosystem.

Below is a list of leading players in the South Korea Leprosy Market:

1. Ministry of Health and Welfare (MOHW)

The Ministry of Health and Welfare (MOHW) oversees national surveillance, infectious disease policy, and the procurement of critical medications.

2. World Health Organization (WHO)

Primary global coordinator for diagnostic protocols and standardizing MDT treatment guidelines.

3. Novartis

Global leader in leprosy elimination efforts and the primary provider of MDT through international donation programs.

4. Handok Inc.

A key domestic pharmaceutical partner known for its strong portfolio in specialty medicines and long-standing presence in the Korean anti-infective market.

5. Daewon Pharmaceutical

Significant domestic player contributing to the production and supply of essential anti-infective medications within the national system.

6. JW Pharmaceutical

Focuses on the supply of essential drugs and supporting the infrastructure for the treatment of rare and infectious conditions.

7. Boryung

Major pharmaceutical entity providing high-efficacy treatments and broad support for South Korea’s infectious disease management.

8. SK Chemicals

Innovative developer focusing on advanced drug delivery systems that improve compliance in chronic treatment regimens.

9. Celltrion

Contributes to the biotechnology-driven development of high-quality therapeutic solutions for global and local health challenges.

10. Samsung Biologics

Leading contract manufacturing organization providing the production capacity necessary for complex biological and chemical drug components.

Emerging Companies in the South Korea Leprosy Market: FAQs